Ranibizumab, a mAb against VEGF-A for the potential treatment of age-related macular degeneration and other ocular complications
{{output}}
Genentech Inc and Novartis Ophthalmics AG have developed and launched the humanized anti-VEGF antibody fragment ranibizumab, a 48-kDa humanized antibody fragment that inhibits all forms of biologically active VEGF-A, for the treatment of age-related macular de... ...
